Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 7/20 | 0.71 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | BCHE | P06276 | 3/20 | 0.56 |
| ▸ | ACHE | P22303 | 3/20 | 0.56 |
| ▸ | BACE1 | P56817 | 3/20 | 0.56 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.50 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.50 |
| ▸ | DRD2 | P14416 | 1/20 | 0.50 |
| ▸ | DRD3 | P35462 | 1/20 | 0.50 |
| ▸ | FABP6 | P51161 | 1/20 | 0.49 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.49 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.49 |
| ▸ | RB1 | P06400 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7723868 | 0.89 | GRIN2B (0.66) | GRIN2BMEN1KMT2ARAB9ABCHE | |
| SCHEMBL663239 | 0.84 | GRIN2B (0.74) | GRIN2BMEN1KMT2ARAB9ABCHE | |
| SCHEMBL866770 | 0.83 | GRIN2B (1.00) | GRIN2BMEN1KMT2ARAB9ABCHE | |
| SCHEMBL8521300 | 0.82 | GRIN2B (0.73) | GRIN2BMEN1KMT2AOPRM1OPRL1 | |
| SCHEMBL7323659 | 0.82 | POLB (0.67) | GRIN2BMEN1KMT2ARAB9ABCHE | |
| Hydrochloric Acid SCHEMBL2550113 | 0.82 | MEN1 (0.78) | GRIN2BMEN1KMT2ARAB9ABCHE | |
| Bicarbonate SCHEMBL11118446 | 0.81 | GRIN2B (0.65) | GRIN2BMEN1KMT2ARAB9ABCHE | |
| SCHEMBL4173336 | 0.80 | GRIN2B (0.69) | GRIN2BMEN1KMT2ARAB9ABCHE | |
| SCHEMBL2954218 | 0.80 | GRIN2B (0.69) | GRIN2BMEN1KMT2ARAB9ABCHE | |
| SCHEMBL433970 | 0.80 | GRIN2B (0.69) | GRIN2BMEN1KMT2ARAB9ABCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111925357-B | Acylhydrazone compound, pharmaceutical composition and application thereof | 中国科学院昆明植物研究所 | 2023-06-06 | — | — | CN | disclosed |
| US-20230027752-A1 | OPIOID RECEPTOR AGONIST, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | FUDAN UNIVERSITY (CN) | 2023-01-26 | — | — | US | disclosed |
| EP-3495341-B1 | PREPARATION PROCESS OF PERFLUOROALKYL COMPOUND WITH MONOHYDROPERFLUOROALKANE AS STARTING MATERIAL | KANTO DENKA KOGYO KK (JP) | 2022-11-02 | — | — | EP | disclosed |
| CN-109563016-B | Method for producing perfluoroalkyl compound using monohydroperfluoroalkane as starting material | 关东电化工业株式会社 | 2022-05-13 | — | — | CN | disclosed |
| CN-112759538-B | 3- (dimethylaminomethyl) cyclohexan-4-ol derivative, preparation method and pharmaceutical application thereof | 复旦大学 | 2022-01-18 | — | — | CN | disclosed |
| CN-112759538-A | 3- (dimethylaminomethyl) cyclohexan-4-ol derivative, preparation method and pharmaceutical application thereof | 复旦大学 | 2021-05-07 | — | — | CN | disclosed |
| US-10450253-B2 | Preparation process of perfluoroalkyl compound with monohydroperfluoroalkane as starting material | KANTO DENKA KOGYO CO., LTD. (JP) | 2019-10-22 | — | — | US | disclosed |
| EP-3495341-A1 | METHOD FOR PRODUCING PERFLUOROALKYL COMPOUND USING MONOHYDROPERFLUOROALKANE AS STARTING MATERIAL | Kanto Denka Kogyo Co., Ltd. (JP) | 2019-06-12 | — | — | EP | disclosed |
| US-20190169107-A1 | PREPARATION PROCESS OF PERFLUOROALKYL COMPOUND WITH MONOHYDROPERFLUOROALKANE AS STARTING MATERIAL | NATIONAL UNIVERSITY CORPORATION GUNMA UNIVERSITY (JP) | 2019-06-06 | — | — | US | disclosed |
| US-20160046625-A1 | BENZIMIDAZOLE AND AZABENZIMIDAZOLE COMPOUNDS THAT INHIBIT ANAPLASTIC LYMPHOMA KINASE | AMGEN INC (US) | 2016-02-18 | — | — | US | disclosed |
| US-20160046625-A1 | BENZIMIDAZOLE AND AZABENZIMIDAZOLE COMPOUNDS THAT INHIBIT ANAPLASTIC LYMPHOMA KINASE | AMGEN INC (US) | 2016-02-18 | — | — | US | disclosed |
| US-9115127-B2 | Benzimidazole and azabenzimidazole compounds that inhibit anaplastic lymphoma kinase | AMGEN INC. (US) | 2015-08-25 | — | — | US | disclosed |
| US-9115127-B2 | Benzimidazole and azabenzimidazole compounds that inhibit anaplastic lymphoma kinase | AMGEN INC. (US) | 2015-08-25 | — | — | US | disclosed |
| US-9115127-B2 | Benzimidazole and azabenzimidazole compounds that inhibit anaplastic lymphoma kinase | AMGEN INC. (US) | 2015-08-25 | — | — | US | disclosed |
| US-20130217668-A1 | BENZIMIDAZOLE AND AZABENZIMIDAZOLE COMPOUNDS THAT INHIBIT ANAPLASTIC LYMPHOMA KINASE | AMGEN INC. (US) | 2013-08-22 | — | — | US | disclosed |
| US-20130217668-A1 | BENZIMIDAZOLE AND AZABENZIMIDAZOLE COMPOUNDS THAT INHIBIT ANAPLASTIC LYMPHOMA KINASE | AMGEN INC. (US) | 2013-08-22 | — | — | US | disclosed |
| US-20130217668-A1 | BENZIMIDAZOLE AND AZABENZIMIDAZOLE COMPOUNDS THAT INHIBIT ANAPLASTIC LYMPHOMA KINASE | AMGEN INC. (US) | 2013-08-22 | — | — | US | disclosed |
| EP-2611784-A1 | BENZIMIDAZOLE AND AZABENZIMIDAZOLE COMPOUNDS THAT INHIBIT ANAPLASTIC LYMPHOMA KINASE | Amgen, Inc (US) | 2013-07-10 | — | — | EP | disclosed |
| WO-2012018668-A1 | BENZIMIDAZOLE AND AZABENZIMIDAZOLE COMPOUNDS THAT INHIBIT ANAPLASTIC LYMPHOMA KINASE | AMGEN INC. (US) | 2012-02-09 | — | — | WO | disclosed |
| WO-2012018668-A1 | BENZIMIDAZOLE AND AZABENZIMIDAZOLE COMPOUNDS THAT INHIBIT ANAPLASTIC LYMPHOMA KINASE | AMGEN INC. (US) | 2012-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160046625-A1 | BENZIMIDAZOLE AND AZABENZIMIDAZOLE COMPOUNDS THAT INHIBIT ANAPLASTIC LYMPHOMA KINASE | BCL6, DCK, FLI1 | GRIN2B 2491/4885MEN1 1707/4885KMT2A 493/4885 |
| US-20230027752-A1 | OPIOID RECEPTOR AGONIST, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | OPRM1, OPRD1, OPRL1 | GRIN2B 533/4885MEN1 4579/4885KMT2A 1648/4885 |
| US-20130217668-A1 | BENZIMIDAZOLE AND AZABENZIMIDAZOLE COMPOUNDS THAT INHIBIT ANAPLASTIC LYMPHOMA KINASE | BCL6, DCK, FLI1 | GRIN2B 2491/4885MEN1 1707/4885KMT2A 493/4885 |
| US-20190169107-A1 | PREPARATION PROCESS OF PERFLUOROALKYL COMPOUND WITH MONOHYDROPERFLUOROALKANE AS STARTING MATERIAL | PFKFB1, PFKFB4, PFAS | GRIN2B 2569/4885MEN1 1558/4885KMT2A 543/4885 |
| US-10450253-B2 | Preparation process of perfluoroalkyl compound with monohydroperfluoroalkane as starting material | PFKFB1, PFKFB4, PFAS | GRIN2B 2569/4885MEN1 1558/4885KMT2A 543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.